Cohance Lifesciences: Update on USFDA inspection at Pashamylaram Manufacturing facility
Cohance Lifesciences (COHANCE) filed a disclosure titled "Update on USFDA inspection at Pashamylaram Manufacturing facility". The company is valued at about ₹16,588 crore.
What happened
Cohance Lifesciences (COHANCE) filed a disclosure with the exchanges on 7 November 2026 at 11:11 AM titled "Update on USFDA inspection at Pashamylaram Manufacturing facility".
Company snapshot
Cohance Lifesciences is a small-cap company in the Healthcare sector, with a market value of about ₹16,588 crore.
The stock last traded at ₹433.6, against a 52-week range of ₹266.7–₹724.1 (40.1% below the high).
Before this filing the shares had moved −1.8% over the month and +2.3% over three months. Average daily turnover over the last 20 sessions was about ₹33.48 crore.
Promoters held 57.48% at the end of Q2 FY27, down 0.01% points from the previous quarter; 94.56% of promoter shares were pledged. Foreign institutions owned 7.71% and domestic institutions 18.86%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 1,105 | 123 | 3.22 |
| Q3 FY26 | 545 | 36.7 | 0.96 |
| Q4 FY26 | 619 | 19.6 | 0.51 |
| Q1 FY27 | 422 | -24.1 | -0.63 |
| Q2 FY27 | 477 | 2.3 | 0.4 |
What history shows
BCEIE's records show 3 previous approval filings from the company since May 2026.
After those filings, the stock gained 2.0% on average the next trading day and was up 1.3% on average after five days (3 filings with price data).
Across 123 similar disclosures by other Healthcare companies, shares moved +0.5% on average the next day and +1.2% over five days; 52% of them rose the next day.
Market-wide, 1,587 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 48% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 21 Sept 2026 | 'Completion of USFDA Inspection'. | +3.4% | +4.0% |
| 5 Sept 2026 | Completion of USFDA Inspection | −1.1% | −3.6% |
| 5 Aug 2026 | Completion of USFDA Inspection | +3.8% | +3.4% |
In the news
Recent coverage elsewhere (links open the original publisher):
- COHANCE Stock Price and Chart — NSE:COHANCE
- Cohance Lifesciences: Can a recovery justify its valuation?
- Cohance Lifesciences manufacturing site in Telangana shut after worker dies in accident
- Cohance Lifesciences to Review September Quarter Results on Nov 6
- Cohance Lifesciences plant ordered shut in Telangana after employee dies in industrial accident
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.